HemaCare (HEMA) Stock Price, News & Analysis

Company Overview

HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.

Key Stats

• Today's Range: $25.31 to $25.31
• 50-Day Range: $25.31 to $25.31
• 52-Week Range: $8.62 to $26.23
• Volume: 5,400 shs
• Average Volume: 39,950 shs
• Market Capitalization: $346.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HEMA Stock Analysis - Frequently Asked Questions

How have HEMA shares performed this year?

HemaCare's stock was trading at $25.31 at the start of the year. Since then, HEMA shares have increased by 0.0% and is now trading at $25.31.
View the best growth stocks for 2025 here.

How do I buy shares of HemaCare?

Shares of HEMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of HemaCare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HemaCare investors own include First Majestic Silver (AG), Warner Bros. Discovery (DISCA), Cognizant Technology Solutions (CTSH), Canadian Solar (CSIQ), Conduent (CNDT), CMC Materials (CCMP) and Athenex (ATNX).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Miscellaneous Health & Allied Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HEMA
• CUSIP: 423498104
• CIK: 801748
• Web: www.hemagen.com
• Phone: 818-226-1968
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 13,691,000
• Free Float: N/A
• Market Cap: $346.52 million
• Optionable: Not Optionable
• Beta: 1.47